Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia

Clinical Biochemistry

Volumn 48, Issue 16-17, 2015, Pages 1113-1119

  van Helden, Josef ^a   Weiskirchen, Ralf ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Method comparison; Performance; PIGF; Preeclampsia; Sandwich immunoassays; SFlt 1; VEGF

Indexed keywords

PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTA PROTEIN;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DILUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMAN; IMMUNOASSAY ANALYZER; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; STANDARD; BIOASSAY; BLOOD; IMMUNOASSAY; PRE-ECLAMPSIA; PREGNANCY; PROCEDURES; REPRODUCIBILITY; SECOND TRIMESTER PREGNANCY;

ADULT; BIOLOGICAL ASSAY; BIOMARKERS; FEMALE; GESTATIONAL AGE; HUMANS; IMMUNOASSAY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PREGNANCY TRIMESTER, SECOND; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84947026504     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.06.020     Document Type: Article

References (23)

1. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science 2005, 308:1592-1594.
2. Walker J.J. Pre-eclampsia. Lancet 2000, 356:1260-1265.
3. Hypertension in pregnancy 2013, American College of Obstetricians and Gynecologists, Washington, D.C., (http://www.acog.org/Resources_And_Publications/Task_Force:and_Work_Group_Reports/Hypertension_in_Pregnancy. Accessed Dec. 12, 2013).
4. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., Schisterman E.F., Thadhani R., Sachs B.P., Epstein F.H., Sukhatme V.P., Karumanchi S.A. Circulating angiogenetic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350:672-683.
5. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenetic factors and implications of later cardiovascular disease. Circulation 2011, 1213:2856-2869.
6. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Mondal S., Liberman T.A., Morgan J.P., Selke F.W., Stillman I.E., Epstein F.H., Sukhatme V.P., Karumanchi S.A. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003, 111:649-658.
7. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placental growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 1994, 269:25646-25654.
8. Thadhani R., Mutter W.P., Wolf M., Levine R.J., Taylor R.N., Sukhatme V.P., Ecker J., Karumanchi S.A. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J. Clin. Endocrinol. Metab. 2004, 89:770-775.
9. Staff A.C., Braekke K., Harsem N.K., Lyberg T., Holthe M.R. Circulating concentrations of s-Flt-1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2005, 122:33-39.
10. Verlohren S., Galindo A., Schlembach D., Zeisler H., Herraiz I., Moertl M.G., Pape J., Dudenhausen J.W., Denk B., Stephan H. An automated method for the determination of the sFlt-1/PlGF ration in the assessment of preeclampsia. Am. J. Obstet. Gynecol. 2010, 202:161. (e.1-161.e11).
11. Benton S.J., Hu Y., Xie F., Kupfer K., Lee S.W., Magee L.A., von Dadelszen P. Angiogenic factors as a diagnostic test for preeclampsia: a performance comparison between two commercial immunoassays. Am. J. Obstet. Gynecol. 2011, 205(469):e1-e8.
12. Mathis G. Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin. Chem. 1993, 39:1953-1959.
13. Lee W.Y. Tris (2,2'-bipyridyl)ruthenium(II) electrogenerated chemiluminescence in analytical science. Mikrochim. Acta 1997, 127:19-39.
14. Armbruster D.A., Pry T. Limit of blank, limit of detection and limit of quantitation. Clin. Biochem. Rev. 2008, 29:49-52.
15. Steinbach G., Rau B., Debard A.L., Javourez J.F., Bienvenue J., Ponzio A., Bonfà A., Hubl W., Demant T., Külpmann W.R., Buchholz J., Schumann G. Multicenter evaluations of a new immunoassay for procalcitonin measurement on the Kryptor system. Clin. Chem. Lab. Med. 2004, 42:440-449.
16. Passing H., Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I. J. Clin. Chem. Clin. Biochem. 1983, 21:709-720.
17. Bland J.M., Altman D.G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986, 8:307-310.
18. Verlohren S., Herraiz I., Lapaire O., Schlembach D., Zeisler H., Calda P., Sabria J., Markfeld Erol F., Galindo A., Schoofs K., Denk B., Stepan H. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014, 63:346-352.
19. Schiettecatte J., Russcher H., Anckaert E., Mees M., Leeser B., Tirelli A.S., Fiedler G.M., Luthe H., Denk B., Smitz J. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin. Biochem. 2010, 43:768-770.
20. Anderson L.B., Frederiksen-Moller B., Work Havelund K., Dechend R., Jorgensen J.S., Jensen B.L., Nielsen J., Lykkedegn S., Barington T., Christesen H.T. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1/placental growth factor ratio: an inter-assay comparison. J. Am. Soc. Hypertens. 2015, 9:86-96.
21. Nucci M., Poon L.C., Demirdjian G., Darbouret B., Nicolaides K.H. Maternal serum placental growth factor isoforms 1 and 2 at 11-13, 20-24 and 30-34weeks' gestation in late onset pre-eclampsia and small of gestational age neonates. Fetal Diagn. Ther. 2014, 35:249-257.
22. Nucci M., Poon L.C., Demirdjian G., Darbouret B., Nicolaides K.H. Maternal serum placental growth factor (PlGF) isoforms 1 and 2 at 11-13weeks' gestation in normal and pathological pregnancies. Fetal Diagn. Ther. 2014, 36:106-116.
23. Lehnen H., Mosblech N., Reineke T., Puchooa A., Menke-Möllers I., Zechner U., Gembruch U. Prenatal clinical assessment of sFlt-1 (soluble fms-like tyrosine kinase 1)/PlGF (placental growth factor) ratio as a diagnostic tool for preeclampsia, pregnancy-induced hypertension, and proteinuria. Geburtshilfe Frauenheilkd. 2013, 73:440-445.